search
Back to results

ISIS 1 Therapeutic Effectiveness

Primary Purpose

OSAS (Obstructive Sleep Apneas Syndrome)

Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
titration night
Sponsored by
Tyco Healthcare Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for OSAS (Obstructive Sleep Apneas Syndrome)

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patient male or female, aged 18 to 75 years
  • weight > 30kg
  • patient with a newly diagnosed OSAS, under treatment with CPAP
  • patient in stable condition
  • patient affiliated to a social security insurance
  • having given its written informed consent to participate to the study

Exclusion Criteria:

  • pneumothorax or pneumomediastin history
  • massive epistaxis (current or previous)
  • decompensated heart failure or hypotension
  • pneumoencephal history, recent trauma or surgery sequel with cranio-nasopharyngeal fistula
  • acute sinusitis history, middle ear infection or perforation of the tympanic membrane
  • respiratory insufficiency or severe respiratory illness with the possibility of residual hypoxemia
  • severe bullous emphysema or previously complicated pneumothorax
  • severe claustrophobia

Sites / Locations

  • Hospital Michalon, sleep disorders centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

A

B

C

D

Arm Description

Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow

Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast

Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow

Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast

Outcomes

Primary Outcome Measures

To determine the sensitivity and specificity of the CPAP/autoCPAP Sandman in adequately detecting respiratory events and to evaluate the therapeutic effectiveness of the device in improving sleep quality and normalizing respiratory events

Secondary Outcome Measures

To compare effective pressure Peff determined by the device and during manual titration
To compare the impact of the two-speed descent pressure algorithm

Full Information

First Posted
March 25, 2008
Last Updated
March 25, 2008
Sponsor
Tyco Healthcare Group
search

1. Study Identification

Unique Protocol Identification Number
NCT00646477
Brief Title
ISIS 1 Therapeutic Effectiveness
Official Title
Therapeutic Efficacy Evaluation of the CPAP/autoCPAP Sandman in the Treatment of New Patients With Obstructive Sleep Apnoea Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
March 2008
Overall Recruitment Status
Unknown status
Study Start Date
October 2007 (undefined)
Primary Completion Date
May 2008 (Anticipated)
Study Completion Date
May 2008 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Tyco Healthcare Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is a prospective field evaluation to assess the therapeutic value of the CPAP/autoCPAP Sandman in 24 new diagnosed Obstructive Sleep Apneic patients. Precisely, the study was designed to : evaluate the therapeutic efficacy of the CPAP/autoCPAP Sandman device in improving sleep quality and normalozing respiratory events determine the sensitivity and specificity of the device in adequately detecting respiratroy events compare effective pressure Peff determined by the device and during manual titration compare the impact of the two-speed descent pressure algorithm
Detailed Description
During the study, each patient underwent one night of full polysomnography with two consecutives therapeutic sequences during the same night, after randomization of the passage order: autotitrating pressure phase: sleep parameters and respiratory events vs results of the polysomnographic registration, manual titration phase: concordance between events respiratory analyzed on the polysomnographic recordings and the events detected by the CPAP / auto-CPAP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
OSAS (Obstructive Sleep Apneas Syndrome)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
Arm Title
B
Arm Type
Experimental
Arm Description
Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
Arm Title
C
Arm Type
Experimental
Arm Description
Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
Arm Title
D
Arm Type
Experimental
Arm Description
Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
Intervention Type
Device
Intervention Name(s)
titration night
Intervention Description
Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes: in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes. in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events.
Primary Outcome Measure Information:
Title
To determine the sensitivity and specificity of the CPAP/autoCPAP Sandman in adequately detecting respiratory events and to evaluate the therapeutic effectiveness of the device in improving sleep quality and normalizing respiratory events
Time Frame
May 2008
Secondary Outcome Measure Information:
Title
To compare effective pressure Peff determined by the device and during manual titration
Time Frame
May 2008
Title
To compare the impact of the two-speed descent pressure algorithm
Time Frame
May 2008

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patient male or female, aged 18 to 75 years weight > 30kg patient with a newly diagnosed OSAS, under treatment with CPAP patient in stable condition patient affiliated to a social security insurance having given its written informed consent to participate to the study Exclusion Criteria: pneumothorax or pneumomediastin history massive epistaxis (current or previous) decompensated heart failure or hypotension pneumoencephal history, recent trauma or surgery sequel with cranio-nasopharyngeal fistula acute sinusitis history, middle ear infection or perforation of the tympanic membrane respiratory insufficiency or severe respiratory illness with the possibility of residual hypoxemia severe bullous emphysema or previously complicated pneumothorax severe claustrophobia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Veronique Grillier-Lanoir
Organizational Affiliation
Tyco Healthcare Group
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital Michalon, sleep disorders center
City
Grenoble
ZIP/Postal Code
38049
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Louis PEPIN, Pr
Phone
+33 4 76 76 55 16
Email
JLPepin@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Patrick Levy, Pr
First Name & Middle Initial & Last Name & Degree
Jean-Louis Pepin, Pr
First Name & Middle Initial & Last Name & Degree
Renaud Tamisier, Dr

12. IPD Sharing Statement

Learn more about this trial

ISIS 1 Therapeutic Effectiveness

We'll reach out to this number within 24 hrs